Table 1. Baseline characteristics of patients with BRCA1/2 mutation advanced recurrent ovarian cancer treated with olaparib.

Baseline Criteria		N (%)
Study subjects		108
Age, Year Median (Range)		55 (38-79)
Tumor type	High grade serous	83 (77%)
	Endometrioid	8 (7.4%)
	Others	9 (8.2%)
	Unknown	8 (7.4%)
Stage at diagnosis	1	1 (0.9%)
	2	10 (9.3%)
	3	76 (70.3%)
	4	11 (10.2%)
	Unknown	10 (9.3%)
Optimally debulked?	Yes	58 (53.7%)
	No	20 (18.5%)
	Unknown	30 (27.8%)
BRCA1/2 mutation	BRCA1	78 (79%)
	BRCA2	30 (21%)
Past Medical History of Breast Cancer	Yes	40 (38%)
	No	68 (62%)
Previous breast cancer chemotherapy	Yes	20 (18.5%)
	No	88 (81.5%)
Platinum status at enrolment to Olaparib	Platinum-Sensitive	65 (60.1%)
	Platinum-Resistant	38 (35.2%)
	Unknown	5 (4.7%)